首页> 外文期刊>Annals of Surgery >Erythropoietin protects critically perfused flap tissue.
【24h】

Erythropoietin protects critically perfused flap tissue.

机译:促红细胞生成素可保护临界灌注皮瓣组织。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: The objective of this study was to analyze whether erythropoietin (EPO) protects from necrosis of critically perfused musculocutaneous tissue and the mechanisms by which this protection is achieved. BACKGROUND: EPO is the regulator of erythropoiesis and is used to treat patients with anemia of different causes. Recent studies suggest that EPO has also other tissue-protective effects, irrespective of its erythropoietic properties. MATERIAL AND METHODS: C57BL/6-mice were treated with 3 doses of EPO at 500 IU/kg intraperitoneally. EPO was given either before (preconditioning, n = 7), before and after (overlapping treatment, n = 7), or after (treatment, n = 7) surgery. Animals receiving only saline served as controls (CON). Acute persistent ischemia was induced by elevating a randomly perfused flap in the back of the animals. This critically perfused tissue demonstrates an initial microvascular failure of approximately 40%, resulting in approximately 50% tissue necrosis if kept untreated. Repetitive fluorescence microscopy was performed over 10 days, assessing angiogenesis, functional capillary density, inflammatory leukocyte-endothelial cell interaction, apoptotic cell death, and tissue necrosis. Additional molecular tissue analyses included the determination of inducible nitric oxide synthase, erythropoietin receptor (EPO-R), and vascular endothelial growth factor (VEGF). RESULTS: EPO preconditioning did not affect hematocrit and EPO-R expression, but increased inducible nitric oxide synthase in the critically perfused tissue. This correlated with a significant arteriolar dilation, which resulted in a maintained functional capillary density (CON: 0 +/- 0 cm/cm(2); preconditioning: 37 +/- 21 cm/cm(2); overlapping treatment: 72 +/- 26 cm/cm(2); P < 0.05). EPO pretreatment further significantly reduced microvascular leukocyte adhesion and apoptotic cell death. Moreover, EPO pretreatment induced an early VEGF upregulation, which resulted in new capillary network formation (CON: 0 +/- 0 cm/cm(2);preconditioning: 40 +/- 3 cm/cm(2); overlapping treatment: 33 +/- 3 cm/cm(2); P < 0.05). Accordingly, EPO pretreatment significantly reduced tissue necrosis (CON: 48% +/- 2%; preconditioning: 26% +/- 3%; overlapping treatment: 20% +/- 3%; P < 0.05). Of interest, EPO treatment was only able to alleviate ischemia-induced inflammation but could not improve microvascular perfusion and tissue survival. CONCLUSIONS: EPO pretreatment improves survival of critically perfused tissue by nitric oxide -mediated arteriolar dilation, protection of capillary perfusion, and VEGF-initiated new blood vessel formation.
机译:目的:本研究的目的是分析促红细胞生成素(EPO)是否能防止严重灌注的肌肉皮肤组织坏死,以及实现这种保护的机制。背景:EPO是促红细胞生成的调节剂,用于治疗不同原因的贫血患者。最近的研究表明,EPO也具有其他组织保护作用,无论其促红细胞生成特性如何。材料与方法:C57BL / 6-小鼠经腹膜内注射3剂EPO,剂量为500 IU / kg。在手术前(预处理,n = 7),手术前后(重叠治疗,n = 7)或手术后(治疗,n = 7)给予EPO。仅接受盐水的动物作为对照(CON)。通过抬高动物背部随机灌注的皮瓣可诱发急性持续性缺血。该严重灌注的组织显示出约40%的初始微血管衰竭,如果不进行治疗,将导致约50%的组织坏死。重复荧光显微镜检查进行了10天,评估了血管生成,功能性毛细血管密度,炎症性白细胞与内皮细胞的相互作用,凋亡性细胞死亡和组织坏死。其他分子组织分析包括确定诱导型一氧化氮合酶,促红细胞生成素受体(EPO-R)和血管内皮生长因子(VEGF)。结果:EPO预处理不会影响血细胞比容和EPO-R的表达,但会增加临界灌注组织中的诱导型一氧化氮合酶。这与显着的小动脉扩张相关,从而导致维持的功能性毛细血管密度(CON:0 +/- 0 cm / cm(2);预处理:37 +/- 21 cm / cm(2);重叠处理:72 + /-26 cm / cm(2); P <0.05)。 EPO预处理可进一步显着减少微血管白细胞粘附和凋亡细胞死亡。此外,EPO预处理可诱导早期VEGF上调,从而导致新的毛细血管网形成(CON:0 +/- 0 cm / cm(2);预处理:40 +/- 3 cm / cm(2);重叠处理:33 +/- 3 cm / cm(2); P <0.05)。因此,EPO预处理可显着减少组织坏死(CON:48%+/- 2%;预处理:26%+/- 3%;重叠治疗:20%+/- 3%; P <0.05)。有趣的是,EPO治疗只能减轻局部缺血引起的炎症,但不能改善微血管灌注和组织存活率。结论:EPO预处理可通过一氧化氮介导的小动脉扩张,保护毛细血管灌注以及VEGF引发的新血管形成,改善临界灌注组织的存活率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号